IONS News and Press, Ionis Pharmaceuticals Inc.

2026-03-09 17:57:59 ET Ionis Pharmaceuticals, Inc. (IONS) Leerink Global Healthcare Conference 2026 March 9, 2026 3:40 PM EDT... Read the full article on Seeking Alpha For further details see: Ionis Pharmaceuticals, Inc. (IONS) Presents at Leerink Global Healthcare Conferenc...

– Lynne Parshall and Joseph Wender to retire at end of term in June 2026 and Peter Reikes to join Ionis Board – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced upcoming transitions on its Board of Directors. B. Lynne Parshall, Esq., and Joseph Wender will ...

2026-03-02 13:27:49 ET Ionis Pharmaceuticals, Inc. (IONS) TD Cowen 46th Annual Health Care Conference March 2, 2026 10:30 AM EST... Read the full article on Seeking Alpha For further details see: Ionis Pharmaceuticals, Inc. (IONS) Presents at TD Cowen 46th Annual Health Care...

2026-03-02 07:18:49 ET More on ARK Invest Tracking Cathie Wood's ARK Invest 13F Portfolio - Q4 2025 Update AI Can't Sustain This Rate Of Return ARKG: Cathie Wood's Biotech Product Is In Rally Mode As Block rallies, just 3 fintech stocks hold A-rated momentum ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), including new analyses from the Phase 3 OASIS-HAE and OASISplus studies. Results will be presented a...

2026-02-27 02:54:16 ET Shares of antisense therapy concern Ionis Pharmaceuticals, Inc. ( IONS ) have rallied strongly since its familial chylomicronemia syndrome med Tryngolza (olezarsen) bore strong data treating severe hypertriglyceridemia. Announced in September 2025, the res...

2026-02-26 16:57:54 ET Ionis Pharmaceuticals, Inc. (IONS) Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 12:00 PM EST... Read the full article on Seeking Alpha For further details see: Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer ...

– PDUFA date set for June 30, 2026 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for olezarsen for severe hypertriglyceridemi...

2026-02-25 15:03:48 ET from Needham issued a price target of $103.00 for IONS on 2026-02-25 19:08:50. The adjusted price target was set to $103.00. At the time of the announcement, IONS was trading at $80.93. The overall price target consensus is at $88.07 with high pric...

2026-02-25 14:15:04 ET Needham analyst issues BUY recommendation for IONS on February 25, 2026 07:08PM ET. The previous analyst recommendation was Buy. IONS was trading at $81.16 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ana...